Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | $15.4M | $65.0M | $74.0M | $19.9M | ($42.8M) | $19.5M | $105.9M | $217.9M | $304.4M | $174.6M | $340.1M | $651.6M | $713.7M | $417.9M | $589.2M | ($104.5M) | $514.8M | $475.8M | $727.3M | $984.8M |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, United Therapeutics Corporation's last 12-month Net Income is $1,110.9M, based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, United Therapeutics Corporation's Net Income growth was 23.5%. The average annual Net Income growth rates for United Therapeutics Corporation have been 39.9% over the past three years, N/A over the past five years.
Over the last year, United Therapeutics Corporation's Net Income growth was 23.5%, which is higher than industry growth of (0.1%). It indicates that United Therapeutics Corporation's Net Income growth is Good.